missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human RNF40 (aa 569-625) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (75%), Rat (75%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-84188 (PA5-84188. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
The protein encoded by this gene contains a RING finger, a motif known to be involved in protein-protein and protein-DNA interactions. This protein was reported to interact with the tumor suppressor protein RB1. Studies of the rat counterpart suggested that this protein may function as an E3 ubiquitin-protein ligase, and facilitate the ubiquitination and degradation of syntaxin 1, which is an essential component of the neurotransmitter release machinery.
Specifications
Specifications
| Accession Number | O75150 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 9810 |
| Name | Human RNF40 (aa 569-625) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 95 kDa retinoblastoma protein binding protein; 95 kDa retinoblastoma-associated protein; AI848422; BRE1 E3 ubiquitin ligase homolog B; Bre1b; BRE1-B; DKFZp686K191; E3 ubiquitin-protein ligase BRE1B; KIAA0661; MGC13051; mKIAA0661; protein staring; Rb-associated protein; RBP95; RING finger protein 40; ring finger protein 40, E3 ubiquitin protein ligase; RING-type E3 ubiquitin transferase BRE1B; Rnf40; STARING; staring protein; syntaxin-1-interacting RING finger protein |
| Common Name | RNF40 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction